Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts Suspension from Quotation January 19, 2026 Sun Summit Minerals January 19, 2026 Transition Metals January 19, 2026
